 |
| Oct-29-14 | Reiterated |
Argus |
Buy |
$140 → $185 |
|
| Oct-28-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$150 → $165 |
|
| Sep-08-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$138 → $150 |
|
| Aug-04-14 | Reiterated |
Argus |
Buy |
$135 → $140 |
|
| Jul-30-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$125 → $138 |
|
| Jul-18-14 | Reiterated |
Deutsche Bank |
Buy |
$144 → $149 |
|
| Apr-23-14 | Reiterated |
Oppenheimer |
Perform |
$121 → $122 |
|
| Mar-21-14 | Reiterated |
Barclays |
Equal Weight |
$115 → $130 |
|
| Jan-31-14 | Reiterated |
Argus |
Buy |
$130 → $135 |
|
| Nov-20-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| Aug-29-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| Aug-27-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| Jul-31-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| Apr-24-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| Apr-15-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| Apr-08-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| Jan-25-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| Jan-24-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| Sep-12-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| Sep-10-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
|
|
| Jan-26-15 08:02AM | Can CAR-T Therapy Live Up To The Biotech IPO Hype? at Investor's Business Daily |
| 06:53AM | Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune |
| 02:46AM | Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race at Forbes |
| Jan-23-15 06:25PM | Will Amgen (AMGN) Keep the Earnings Streak Alive in 4Q? - Analyst Blog Zacks |
| 04:20PM | Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog Zacks |
| 06:15AM | Up to Speed: Death of Saudi king moves needle on oil prices (Video) at American City Business Journals |
| Jan-22-15 07:00PM | UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Zacks |
| 06:35PM | Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog Zacks |
| 06:00PM | BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks |
| 05:40PM | Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Zacks |
| 04:10PM | Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Zacks |
| 04:01PM | Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results PR Newswire |
| 02:06PM | An easier way to understand the pharma industry Market Realist |
| Jan-21-15 06:13PM | Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog Zacks |
| 06:08PM | Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst Blog Zacks |
| 05:00PM | Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Zacks |
| 12:50PM | Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Zacks |
| 11:02AM | Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog Zacks |
| 09:30AM | Drug companies find common ground over Colorado's 'biosimilars' legislation at American City Business Journals |
| Jan-20-15 06:03PM | Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog Zacks |
| 05:00PM | Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Zacks |
| 03:30PM | Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog Zacks |
| 11:55AM | J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst Blog Zacks |
| 10:15AM | Three Market Leading Healthcare Picks at Forbes |
| 07:41AM | Regeneron CEO: Choice, not price best for patients CNBC |
| Jan-19-15 06:35PM | AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog Zacks |
| 07:10AM | 'Biosimilars' law returns to Colorado Legislature; would allow generics to be swapped for biotech drugs at American City Business Journals |
| Jan-16-15 04:45PM | ZIOPHARM, Intrexon Ink CAR T Deal with MD Anderson - Analyst Blog Zacks |
| 04:00PM | Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst Blog Zacks |
| 11:10AM | Hospira Submits Retacrit Regulatory Application to the FDA - Analyst Blog Zacks |
| 09:30AM | Amgen, Rio Tinto, Intel, IBM and Cisco highlighted as Zacks Bull and Bear of the Day - Press Releases Zacks |
| 01:00AM | Bull of the Day: Amgen (AMGN) - Bull of the Day Zacks |
| Jan-15-15 04:01PM | Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer PR Newswire |
| 10:30AM | AstraZeneca Announces Encouraging Data from Brilinta Study - Analyst Blog Zacks |
| Jan-14-15 03:40PM | Amgen Maintains 2015 View, Expects Several Drug Launches - Analyst Blog Zacks |
| 02:39PM | Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog Zacks |
| Jan-13-15 04:28PM | Express Scripts sees opportunity to lower cancer treatment cost Reuters |
| 01:23PM | The Poster Child For Risk and Reward Yahoo Finance Blogs |
| Jan-12-15 04:01PM | Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome PR Newswire |
| 10:15AM | Analyzing Eli Lilly's drug pipeline CNBC |
| Jan-09-15 03:42PM | Regeneron Jumps On Favorable Cholesterol Drug Report at Investor's Business Daily |
| 01:58PM | Regeneron Can Generate 25% Upside for Investors at Barrons.com |
| 10:37AM | Sanofi, Regeneron cholesterol drug also effective in monthly doses Reuters |
| Jan-08-15 04:15PM | FDA panel OKs copy of Amgens Neupogen cancer drug at American City Business Journals |
| 04:15PM | Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference PR Newswire |
| 03:43PM | Does 23andMe Deal Mean Medical Centers Are Sitting On Data Worth Millions? at Forbes |
| 01:31PM | 'Dirty' discovery in antibiotics CNBC |
| 01:28PM | FDA paves way for cheaper cancer drug copies CNBC |
| 08:02AM | 5 Potential Blockbuster Drugs Set To Launch In 2015 at Investor's Business Daily |
| Jan-07-15 05:06PM | Why The FDA Panel's Nod To Sandoz's Filgrastim (Zarzio) Is Good News For Patients at Forbes |
| 04:11PM | Novartis Biosimilar of Amgens Neupogen Wins U.S. Panel Backing at Bloomberg |
| 01:33PM | When You Should Buy Low Beta Stocks Market Realist |
| Jan-06-15 12:07PM | UPDATE: Barclays Initiates Coverage On Amgen Benzinga |
| 10:43AM | Will biotech bull run continue? CNBC |
| Jan-05-15 03:23PM | Amgen announces treatment to compete with Juno, other Seattle biotechs as it exits region at bizjournals.com |
| 02:58PM | Amgen, Kite Pharma team up on immune-based cancer drugs AP |
| 01:13PM | Southern California firms Amgen and Kite team on cancer treatments at Los Angeles Times |
| 12:47PM | FDA Staff Recommends Novartis Biosimilar Version of an Amgen Drug at The Wall Street Journal |
| 12:36PM | [$$] Novartis Wins FDA Staff OK for Neupogen Biosimilar at The Wall Street Journal |
| 12:21PM | Kite Pharma Up On Amgen Cancer Partnership at Investor's Business Daily |
| 10:33AM | Stocks Drop 1% In Rising Volume; Visa Falls 1% at Investor's Business Daily |
| 10:30AM | Amgen, Kite Pharma in Immunotherapy Pact at The Wall Street Journal |
| 10:00AM | Amgen and Kite Pharma in cancer immunotherapy pact at MarketWatch |
| 09:57AM | Amgen, Kite Pharma ink deal to develop cancer immunotherapies Reuters |
| 09:07AM | Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies Benzinga |
| 09:00AM | Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies PR Newswire |
| Jan-02-15 04:30PM | Biotech investor explains why Juno Therapeutics won't be like Dendreon at bizjournals.com |
| Dec-26-14 04:16PM | Nasdaq, Russell 2000 Join New-High Party; GoPro Up Again at Investor's Business Daily |
| 03:07PM | Tesla Motors Up On Battery News; Stocks At Record at Investor's Business Daily |
| Dec-24-14 06:24PM | Biotech Stocks Take A Beating, But Find Support at Investor's Business Daily |
| 04:56PM | Top U.S. Stock Mutual Funds Of 2014: How They Did It at Investor's Business Daily |
| 01:01PM | Are There Any Winners Left In The Biotech Space? Benzinga |
| Dec-23-14 05:48PM | Buy biotech dip? CNBC |
| Dec-22-14 09:15AM | Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts PR Newswire |
| Dec-17-14 05:45PM | Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend PR Newswire |
| 03:11PM | Leaked Sony emails show Loeb influence on studio execs Reuters |
| 01:05PM | Is a Biosimilar (Generic) Top Cancer Drug for You? at 24/7 Wall St. |
| 01:04PM | Amgen Leukemia Treatment to Cost $178,000, Among Priciest Drugs at Bloomberg |
| 12:59PM | Midday Movers: Carnival, Chevron, Netflix & more at CNBC |
| Dec-15-14 04:44PM | Where is Santa rally? Yahoo Finance Blogs |
| 10:04AM | Is This The Future Of Late-Stage Drug Development? at Forbes |
| 09:34AM | Biotech Entrepreneur Tony Coles Takes Aim At Parkinson's And Alzheimer's at Forbes |
| Dec-13-14 08:02AM | Meet 5 Top Biotech Stocks Holding Up In Shaky Market at Investor's Business Daily |
| Dec-11-14 05:38PM | How Can Drugmakers Handle New Pricing Pressures? at Investor's Business Daily |
| 04:01PM | Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1 Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire |
| 03:45PM | bluebird bio (BLUE) Soars on Data from LentiGlobin Study Zacks |
| 06:00AM | How Amgen Makes Billions On Just A Few Drugs at Investopedia |
| Dec-10-14 05:15PM | Equity markets felland fell hard (no recovery like yesterday) Yahoo Finance Blogs |
| 02:10PM | Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data Zacks |
| 08:16AM | The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan Zacks |
| Dec-09-14 05:20PM | Dynavax & AstraZeneca Alter Agreement for Asthma Product Zacks |
| 04:00PM | Amgen Successfully Expands Xgeva Label in the U.S. Zacks |
| 08:02AM | Big-Cap Stock Funds Tend To Lag at Investor's Business Daily |
| Dec-08-14 09:00PM | Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia PR Newswire |
| 06:05PM | Amgen Unveils Positive Results from Blood Cancer Studies Zacks |
| 05:50PM | Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks |
| 04:20PM | New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma PR Newswire |
| 02:17PM | Federal Appeals Court Declines to Address a Crucial Biosimilar Question at The Wall Street Journal |
| 01:12PM | Midday movers: McDonald's, Sony, Celgene & more at CNBC |
| 12:37PM | Celgene CEO: Cancer drug pipeline booming CNBC |
|
|
|
|
| Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| de Carbonnel Francois | Director | Dec 03 | Sale | 168.01 | 3,000 | 504,041 | 19,159 | Dec 03 05:00 PM | | COFFMAN VANCE D | Director | Sep 05 | Option Exercise | 56.79 | 20,000 | 1,135,800 | 41,623 | Sep 09 06:54 PM | | Harper Sean E | EVP, Research & Development | Aug 05 | Sale | 127.29 | 14,000 | 1,782,126 | 59,503 | Aug 07 04:22 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 21 | Option Exercise | 56.64 | 4,130 | 233,911 | 22,719 | May 22 05:15 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 21 | Sale | 112.83 | 4,130 | 465,984 | 18,589 | May 22 05:15 PM | | Bradway Robert A | Chairman, CEO and President | May 12 | Buy | 111.77 | 894 | 99,919 | 185,013 | May 12 08:33 PM | | Michael A Kelly | Acting CFO | Apr 28 | Sale | 110.45 | 2,065 | 228,072 | 41,041 | Apr 29 05:48 PM | | de Carbonnel Francois | Director | Mar 06 | Option Exercise | 54.44 | 10,000 | 544,350 | 25,364 | Mar 07 05:23 PM | | de Carbonnel Francois | Director | Mar 06 | Sale | 126.69 | 1,000 | 126,690 | 18,343 | Mar 07 05:23 PM | | BALTIMORE DAVID | Director | Feb 26 | Option Exercise | 62.55 | 5,000 | 312,750 | 31,879 | Feb 26 08:28 PM | | HENDERSON REBECCA M | Director | Feb 13 | Option Exercise | 62.41 | 20,000 | 1,248,160 | 25,549 | Feb 14 04:34 PM | | HENDERSON REBECCA M | Director | Feb 13 | Sale | 123.53 | 20,000 | 2,470,680 | 5,549 | Feb 14 04:34 PM | | Bradway Robert A | Chairman, CEO and President | Feb 12 | Option Exercise | 62.55 | 65,000 | 4,065,750 | 216,040 | Feb 14 04:19 PM |
|
|
|
|
|
|
